Know Cancer

or
forgot password

A Phase 2 Study of KOS-862 Administered Intravenously Weekly for 3 Weeks Every 4 Weeks, in Patients With Hormone Resistant Prostate Cancer Who Have Progressed Following Initial Therapy for Metastatic Disease


Phase 2
18 Years
N/A
Not Enrolling
Male
Prostate Cancer

Thank you

Trial Information

A Phase 2 Study of KOS-862 Administered Intravenously Weekly for 3 Weeks Every 4 Weeks, in Patients With Hormone Resistant Prostate Cancer Who Have Progressed Following Initial Therapy for Metastatic Disease


This study is a Phase 2, single arm study of KOS-862 in men with metastatic prostate cancer
who have failed a docetaxel-containing regimen. PSA response is the primary end-point and
objective responses will be checked as available.


Inclusion Criteria:



- At least 18 years of age.

- Metastatic disease.

- One previous treatment including docetaxel (Taxotere).

- At least 3 weeks since last surgery/radiation/chemotherapy

- ECOG Performance Status of 0, 1 or 2

Exclusion Criteria:

- Active brain metastases

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

prostate cancer

Authority:

United States: Food and Drug Administration

Study ID:

KOS-202/NO18401

NCT ID:

NCT00104130

Start Date:

December 2004

Completion Date:

February 2005

Related Keywords:

  • Prostate Cancer
  • prostate
  • Prostatic Neoplasms

Name

Location

Washington University School of MedicineSaint Louis, Missouri  63110
Fox Chase Cancer CenterPhiladelphia, Pennsylvania  19111
Georgia Cancer SpecialistsDecatur, Georgia  30033
University of WashingtonSeattle, Washington  98195
Oregon Health & Science UniversityPortland, Oregon  97201
Kaiser Permanente Medical CenterVallejo, California  94589
The Cleveland Clinic FoundationCleveland, Ohio  
University of Maryland Medical SystemBaltimore, Maryland  21201
Kaiser Permanente NW Oncology ClinicPortland, Oregon  97227